Atormac
brintellex
Neurology India
menu-bar5 Open access journal indexed with Index Medicus
  Users online: 3922  
 Home | Login 
About Editorial board Articlesmenu-bullet NSI Publicationsmenu-bullet Search Instructions Online Submission Subscribe Videos Etcetera Contact
  Navigate Here 
 Search
 
  ╗ Next article
  ╗ Previous article 
  ╗ Table of Contents
  
 Resource Links
  ╗  Similar in PUBMED
 ╗  Search Pubmed for
 ╗  Search in Google Scholar for
 ╗Related articles
  ╗  Article in PDF (43 KB)
  ╗  Citation Manager
  ╗  Access Statistics
  ╗  Reader Comments
  ╗  Email Alert *
  ╗  Add to My List *
* Registration required (free)  


  In this Article
   Abstract
   Introduction
   Results and disc...
   References

 Article Access Statistics
    Viewed3560    
    Printed125    
    Emailed1    
    PDF Downloaded98    
    Comments [Add]    

Recommend this journal

   
Year : 2002  |  Volume : 50  |  Issue : 4  |  Page : 537-8

Detection of 1583 bp gene transcript in lymphocytes of muscular dystrophy patients.


Department of Neurology, Postgraduate Institute of Medical Education and Research, Chandigarh - 160 012, India.

Correspondence Address:
Department of Neurology, Postgraduate Institute of Medical Education and Research, Chandigarh - 160 012, India.

  ╗  Abstract

DMD and BMD are X-lined recessive disorders. RAP-PCR was utilized to investigate differentially expressed gene transcripts in lymphocytes from DMD, BMD and normal individuals as possible diagnostic parameter. A 1583 bp transcript was found to be expressed in both DMD and BMD patients which was unrelated to the known dystrophin gene. This may prove helpful in determining the carrier status of DMD/BMD.

How to cite this article:
Prabhakar S, Anand A. Detection of 1583 bp gene transcript in lymphocytes of muscular dystrophy patients. Neurol India 2002;50:537


How to cite this URL:
Prabhakar S, Anand A. Detection of 1583 bp gene transcript in lymphocytes of muscular dystrophy patients. Neurol India [serial online] 2002 [cited 2020 Dec 4];50:537. Available from: https://www.neurologyindia.com/text.asp?2002/50/4/537/1312




   ╗   Introduction Top

DMD and BMD are X-linked muscular dystrophies, the former being fatal and the latter a milder variant. Mutations have been detected in the 2300 bp long dystrophin gene of these patients responsible for such diseased phenotype. The severity of disease is believed to depend upon the degree of deficiency of dystrophin, which is known to act in association with other sarcolemmal glycoproteins.[1]
Various methods like multiplex PCR, Southern analysis,[2] direct sequencing, Western blot analysis,[3] immunocytochemistry, CA repeat analysis,[4] and single-strand conformations polymorphism have been successfully employed as diagnostic tools. Anand et al[5] reported that DMD and BMD are allelic X-linked recessive disorders where three novel transcripts, i.e., 598bp, 849bp and 1583 bp are selectively expressed in patients of muscular dystrophy as compared to normal individuals. 598bp and 849bp transcripts were exclusively present in DMD patients and their families, but not in BMD. All these transcripts were reported to be completely unrelated to dystrophin gene. These studies were conducted exclusively in muscle biopsies. Due to the invasive nature of the procedure, an alternative and convenient means of possible diagnosis was explored by studying the expression of same transcripts in lymphocytes derived from blood. The patients who underwent routine muscle biopsies were subjected to lymphocyte based analysis of RAP-PCR products inorder to ascertain the presence of the these transcripts as diagnostic marker of the DMD/BMD.

Methodology
RNA isolation : About 5 ml of blood was drawn from patients and lymphocytes extracted. RNA from these lymphocytes of DMD, BMD and control subjects was isolated using TRI reagent (Sigma).It was quantified and checked for presence of contaminating DNA after DNAse I treatment.
cDNA synthesis : About 100ng of RNA was used as starting template for cDNA synthesis. For this, about 1 Ál of each arbitrary primer pair (AP) having the following sequence was used.

Following the incubation for 10 min at 700C, the reaction was chilled on ice. About 1 Ál of RNase inhibitor, 1 Ál dNTP mix (25 mM each NTP), 2 Ál of 10x first strand buffer, and 0.5 Ál of MMLV - Reverse transcriptase (5 units/Ál) were mixed and the contents incubated at 370C for 1 hr to allow cDNA synthesis.
RAP PCR : The PCR was performed using the same primer pair as used in cDNA synthesis. All reactions were performed in 50 Ál reaction mixture containing 5 Ál 10x Taq buffer, 3 Ál 25 mM Mgcl2 (3 mM final
concentration), 28.7 Ál of distilled water, 0.2 Ál of Taq polymerase, (5 U/Ál), 2 Ál of 25 mM A1 + A2 primers and 10 Ál 1 : 10 diluted cDNA obtained from previous step. actin RT PCR was performed as control reaction for normalization. The PCR cycles for RAP-PCR and RT-PCR were as [Table I]. RAP-PCR products were visualized by running 6% polyacrylamide - 7 M urea sequencing gel. The gel was removed carefully and vacuum dried on gel drier at 850C x 1Ż hr. Subsequently, it was exposed to KODAK X-OMAT film for 3 days at -20oC. The film was developed and gel pattern obtained. RT PCR products were visualized in 3% agarose gel electrophoresis.


   ╗   Results and discussion Top

Post PCR analysis revealed the presence of 1583 bp gene transcript in patients of DMD/BMD [Table II]. Further, in this study the RNA fingerprints obtained from the PCR were fewer than those obtained from muscle biopsies in the previous study by the authors This RAP-PCR study is conspicuous by the presence of 1583 bp gene transcript in the lymphocytes of DMD/BMD patients, which is along expected lines as reported by us in our study with muscle biopsies.[5]
This could be helpful in convenient diagnosis of muscular dystrophy patients and carriers by blood. This transcript is unrelated to dystrophin gene, known to be implicated in the pathogensis of muscular dystrophy. The expected DMD specific nature of the differentially expressed novel gene transcripts i.e, 849 and 598 bp is amply evident by their absence in the lymphocytes of DMD in the present study. This could be due to DMD specific expression of these transcripts in muscles only which is interestingly not reflected in blood. This could also be due to their decreased expression in lymphocytes as compared to muscles, the prominent site of pathogenesis. As an important aspect of developmental muscle biology the significance of local physiological dynamics governing the pathogenesis of DMD in muscle is reemphasised here in this report. The low expression of RNA fingerprints could be attributed to limited recognition of template by the given primer set. Utilization of another set of arbitrary primers could be a plausible alternative to further any diagnostic applicability of previously reported DMD specific novel transcripts in lymphocytes.


 

  ╗   References Top

1.Koenig M, Hoffman EP, Bertelson CJ et al :Complete cloning to the DMD cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 1987; 50 : 509.   Back to cited text no. 1    
2.Kunkel IM, Monaco AP, Middleworth et al : Specific cloning of DNA fragments absent from the DNA of a male patient with an X chromosome deletion. Proceedings of National Academy of Sciences, U.S.A. 1985; 82 : 4778-4782.   Back to cited text no. 2    
3.Hoffman EP, Brown RH, Kunkel LM : Dystrophin : the product of DMD locus. Cell 1987; 51 : 919-928.   Back to cited text no. 3    
4.Musova Z, Matoska V, Krejcova S et al : Use of CA repeats polymorphism in direct and indirect diagnosis of Duchenne and Becker muscular dystrophy. Cas Lek Cesk 1997; 5, 136(3) : 90-94.   Back to cited text no. 4    
5.Anand A, Prabhakar S, Kaul D : Genetic polymorphism in muscle biopsies of Duchenne and Becker muscular dystrophy patients. Neurol India 1999; 47 : 218-223.   Back to cited text no. 5    

 

Top
Print this article  Email this article
Previous article Next article
Online since 20th March '04
Published by Wolters Kluwer - Medknow